Outpatient versus inpatient care for catheter-based treatment of primary liver cancer (CHOC)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, multicenter comparison of two care pathways — ambulatory (same-day discharge) versus conventional inpatient admission — for patients receiving intra-arterial treatments (TACE or TARE) for primary liver cancer. Participants are followed for seven months to measure patient satisfaction, safety events, and clinical outcomes. The trial embeds a qualitative implementation study and a medico-economic analysis, including cost analysis and a five-year budget impact assessment, to evaluate feasibility, acceptability, adoption, and sustainability. Eligible patients are adults with HCC or iCCA planned for first intra-arterial therapy who meet liver-function and anatomic criteria defined by the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* HCC or iCCA diagnosed according to the criteria of the European Association for the Study of the Liver (2024) or histologically proven.
* Patient with HCC or iCCA eligible for intra-arterial treatment (transarterial chemoembolization \[TACE\] or transarterial radioembolization \[TARE\]), with no prior intra-arterial treatment of the same type as the one planned in the trial:

  * no prior TACE for patients included for TACE;
  * no prior TARE for patients included for TARE. Prior intra-arterial treatment of the other type is allowed (prior TACE before TARE, or prior TARE before TACE). Prior non-intra-arterial treatments are allowed.
* If TACE is proposed at the multidisciplinary tumour board (RCP):

  * Patient Child-Pugh \< B8
  * Single or multiple HCC
  * Absence of lobar or truncal portal obstruction
  * Absence of bile duct dilatation
* If treatment by TARE proposed in RCP:

  * Absence of truncal portal tumor invasion
  * Uni-lobar tumor invasion (except for centrohepatic iCCA)
  * Total bilirubin \< 20 mg/l (or 35 µmol/L)
* Patient affiliated to or benefiting from a social security scheme
* Patient having signed an informed consent form

Exclusion Criteria:

* Technical contraindication or morphological elements of predictable technical difficulty
* Planned combined same-day therapeutic strategies at the index procedure (e.g., TACE combined with percutaneous ablation) are not allowed; sequential (non-same-day) treatments are allowed.
* Chronic renal insufficiency (Clairance \< 30 ml/min)
* Known allergy to a contrast agent or chemotherapy agent
* inability to participate in ambulatory care (inability to understand and follow discharge instructions, lack of reliable telephone access, absence of a responsible accompanying adult for the first night after discharge, or inability to access urgent care in a timely manner if symptoms occur)
* Patient previously included in the study
* Patient who, for psychological, social, family or geographical reasons, could not be regularly monitored, patient who, for psychological, social, family or geographical reasons, could not be followed regularly
* Concomitant disease or severe uncontrolled clinical situation
* Severe uncontrolled infection
* Pregnant, breast-feeding or parturient woman
* Person deprived of liberty by judicial or administrative decision
* Person under compulsory psychiatric care
* Person under a legal protection measure
* Person unable to give consent

Where it's running

• University hospital of Amiens
  Amiens, France Recruiting
• University hospital of Angers
  Angers, France Recruiting
• University hospital of Besançon
  Besançon, France Recruiting
• Hospital of Avicennes (AP-HP)
  Bobigny, France Recruiting
• University hospital of Brest
  Brest, France Recruiting
• Hospital of Beaujon (AP-HP)
  Clichy, France Recruiting

Study contacts

• Principal investigator: Christophe AUBE, Pr — University Hospital, Angers
• Study coordinator: Christophe AUBE, Pr
• Email: ChAube@chu-angers.fr
• Phone: +33(0)24-135-4281

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anatomic vs nonanatomic liver resection after conversion therapy for liver cancer

  This study tests whether removing more precisely targeted liver tissue (anatomic resection) works better than removing tissue more broadly (nonanatomic) for patients whose unresectable liver cancer became eligible for surgery after PD-1/PD-L1–based therapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07927452

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Durvalumab plus histotripsy for intrahepatic cholangiocarcinoma

  This study tests whether adding histotripsy to ongoing durvalumab helps people with advanced intrahepatic cholangiocarcinoma by boosting the immune response and checking safety.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07766187

• Impact of Anesthesia on Inflammation and NETosis During HCC Ablation

  This study tests whether a propofol–fentanyl anesthesia plan with lidocaine during radiofrequency ablation for hepatocellular carcinoma affects inflammation and NETosis in patients with small tumors.

  Recruiting Iuliu Hatieganu University of Medicine and Pharmacy · Cluj-Napoca, Cluj · NCT07657897

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• Chidamide plus chemotherapy and immunotherapy for advanced intrahepatic cholangiocarcinoma

  This trial will test whether adding the oral drug chidamide to gemcitabine/cisplatin and an immune checkpoint inhibitor helps people with unresectable or metastatic intrahepatic cholangiocarcinoma who have not had prior systemic therapy.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07570849

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.